Mississauga to make Moderna COVID-19 vaccine drug substance for global distribution
Published September 9, 2021 at 3:32 pm
The drug substance for the Moderna COVID-19 vaccine will be made in Mississauga under an agreement announced today.
Moderna Inc.’s multi-year pact with National Resilience Inc., which is seeking to build the world’s most advanced biopharmaceutical manufacturing ecosystem, means National Resilience will produce mRNA for the Moderna COVID-19 vaccine at its Mississauga facility for distribution worldwide.
National Resilience was founded last November and recently acquired the Mississauga manufacturing plant.
“Moderna’s COVID-19 vaccine has saved countless lives, and we’re excited to manufacture mRNA for this important vaccine,” said National Resilience CEO Rahul Singhvi. “This collaboration has the potential to ensure more people are protected around the world from the deadly COVID-19 virus.”
Separately, U.S.-based Moderna recently announced a collaboration to bring mRNA manufacturing to Canada through a Memorandum of Understanding with the government of Canada to build a state-of-the-art facility here.
Mississauga, which already boasts a significant life sciences sector, has asked Moderna to build its facility here.
According to the City of Mississauga, Mississauga is the first and only municipality in Canada to have a comprehensive Life Sciences Cluster Strategy in place. According to the city’s website, Mississauga is the second-largest life sciences sector in Canada.
insauga's Editorial Standards and Policies